跳至主要内容
临床试验/EUCTR2022-003266-21-AT
EUCTR2022-003266-21-AT招募中1 期

Acute effects of ketamine on the glutamatergic NMDA receptor quantified by PET and the radioligand (R)-[11C]-Me-NB1 - Ketamine, acute effects

Medical University of Vienna0 个研究点目标入组 24 人开始时间: 2022年12月5日最近更新:
相关药物

试验速览

阶段
1 期
状态
招募中
入组人数
24

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • - General health based on medical history, physical examination and structured clinical interview for DSM-V (SCID)
  • - Age 18 to 55 years
  • - Willingness and competence to sign the informed consent form
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 55
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • - Current or history of psychiatric or neurological disease
  • - Current medical illness requiring treatment
  • - Current or former psychopharmacological treatment
  • - Pregnancy or currently breastfeeding
  • - Current or former substance abuse
  • - Any contraindication for MRI e.g. (implants, stainless steel graft)
  • - Failure to comply with the study protocol or to follow the instruction of the investigating team
  • - If the radiation exposure by PET or SPECT or CT during scientific study participation in the last 10 years exceeds 30 mSv

研究者

相似试验